AR059629A1 - Inhibidores del inhibidor del activador de plasminogeno (pai- 1) para el tratamiento de trastornos musculares - Google Patents
Inhibidores del inhibidor del activador de plasminogeno (pai- 1) para el tratamiento de trastornos muscularesInfo
- Publication number
- AR059629A1 AR059629A1 ARP070100784A ARP070100784A AR059629A1 AR 059629 A1 AR059629 A1 AR 059629A1 AR P070100784 A ARP070100784 A AR P070100784A AR P070100784 A ARP070100784 A AR P070100784A AR 059629 A1 AR059629 A1 AR 059629A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- muscle
- perfluoroalkyl
- alkyl
- pyridinyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 title 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 title 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 title 2
- 208000029578 Muscle disease Diseases 0.000 title 1
- 208000021642 Muscular disease Diseases 0.000 title 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 6
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 210000003205 muscle Anatomy 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 206010028289 Muscle atrophy Diseases 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004076 pyridyl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000029549 Muscle injury Diseases 0.000 abstract 2
- 201000000585 muscular atrophy Diseases 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- -1 2 -pyridinyl Chemical group 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 abstract 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Métodos noveles para el tratamiento de lesiones musculares, pérdida de masa muscular, degeneracion muscular, atrofia muscular o tasas reducidas de reparacion muscular asociada a varios trastornos como la distrofia muscular mediante el uso de inhibidores del PAI-1 de molécula pequena Reivindicacion 1: Un método para tratar lesiones musculares, pérdida de masa muscular, degeneracion muscular, atrofia muscular o una tasa reducida de reparacion muscular, que comprende la administracion de una cantidad efectiva de un compuesto de la formula (1), o una forma farmacéuticamente aceptable de la sal, solvato o éster correspondientes, a un mamífero que lo necesite: donde: X es un enlace químico, -CH2- o -C(O)-; R1 es alquilo C1-8, (-CH2)n- cicloalquilo C3-6, donde n es un numero entero de 0 a 3, piridinilo, -CH2-piridinilo, fenilo o bencilo, los anillos de los grupos cicloalquilo, piridinilo, fenilo y bencilo se pueden sustituir de forma opcional, de entre 1 a 3 grupos seleccionados de entre, un halogeno, alquilo C1-4, perfluoroalquilo C1-3, -O-perfluoroalquilo C1-3, alcoxi C1-3, -OH, -NH2, o -NO2; R2 es H, alquilo C1-6, cicloalquilo C3-6, -CH2-cicloalquilo C3-6, perfluoroalquilo C1-3, -CH2OH o CH2OAc; R3 es H, un halogeno, alquilo C1-6, perfluoroalquilo C1-3, alcoxi C1-6, cicloalquilo C3-6, -CH2-cicloalquilo C3-6, cicloalquenilo C3-6, --CH2-cicloalquenilo C3-6, -NH2, o -NO2; R4 es cicloalquilo C3-6, -CH2-cicloalquilo C3-6, cicloalquenilo C3-6, -CH2-cicloalqueniIo C3- 6, fenilo, bencilo, piridinilo, o -CH2-piridinilo, en el que los anillos de estos grupos se pueden sustituir opcionalmente por de 1 a 3 grupos seleccionados de entre un halogeno, alquilo C1-4, perfluoroalquilo C1-3, -O-perfluoroalquilo C1-3, alcoxi C1-3, -OH, -NH2, -NO2 o (CO)-alquilo C1-6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77752106P | 2006-02-27 | 2006-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059629A1 true AR059629A1 (es) | 2008-04-16 |
Family
ID=38438022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100784A AR059629A1 (es) | 2006-02-27 | 2007-02-26 | Inhibidores del inhibidor del activador de plasminogeno (pai- 1) para el tratamiento de trastornos musculares |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070203220A1 (es) |
| EP (1) | EP2010171A2 (es) |
| JP (1) | JP2009528290A (es) |
| KR (1) | KR20080108407A (es) |
| CN (1) | CN101384256A (es) |
| AR (1) | AR059629A1 (es) |
| AU (1) | AU2007217363A1 (es) |
| BR (1) | BRPI0710964A2 (es) |
| CA (1) | CA2643731A1 (es) |
| CR (1) | CR10253A (es) |
| EC (1) | ECSP088699A (es) |
| GT (1) | GT200800167A (es) |
| IL (1) | IL192975A0 (es) |
| MX (1) | MX2008011015A (es) |
| NO (1) | NO20083438L (es) |
| PE (1) | PE20071017A1 (es) |
| RU (1) | RU2008128475A (es) |
| TW (1) | TW200744585A (es) |
| WO (1) | WO2007098278A2 (es) |
| ZA (1) | ZA200807357B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2049520A4 (en) * | 2006-08-07 | 2011-01-05 | Ironwood Pharmaceuticals Inc | indole compounds |
| GB0812192D0 (en) * | 2008-07-03 | 2008-08-13 | Lectus Therapeutics Ltd | Calcium ion channel modulators & uses thereof |
| AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
| CN103724357B (zh) * | 2012-10-11 | 2016-06-08 | 中国药科大学 | 一种3,4-二氢吡喃并[3,2-b]吲哚-2-酮类化合物的合成方法 |
| WO2017073060A1 (ja) * | 2015-10-29 | 2017-05-04 | 国立大学法人東北大学 | コラーゲン産生抑制剤 |
| EP3429636A4 (en) * | 2016-03-17 | 2019-11-20 | Vanderbilt University | IMPROVEMENT OF PLASMINACTIVITY FOR PREVENTING SOFT TISSUE CALIBRATION |
| CA3182911A1 (en) * | 2020-05-11 | 2021-11-18 | Talengen International Limited | Method and drug for treating spinal muscular atrophy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI224101B (en) * | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| TW591020B (en) * | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US7291639B2 (en) * | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| PT1397130E (pt) * | 2001-06-20 | 2007-11-13 | Wyeth Corp | Derivados ácidos de indole substituído como inibidores de inibidor 1 do activador de plasminogénio (pai-1) |
| TWI240723B (en) * | 2001-06-20 | 2005-10-01 | Wyeth Corp | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| EP1569901B1 (en) * | 2002-12-10 | 2008-10-15 | Wyeth | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) |
| UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| JP2006514640A (ja) * | 2002-12-10 | 2006-05-11 | ワイス | プラスミノゲンアクティベータインヒビターのインヒビターとしての置換３−アルキル及び３−アリールアルキル１ｈ−イル酢酸誘導体 |
| CA2509222A1 (en) * | 2002-12-10 | 2004-06-24 | Wyeth | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| MXPA05006288A (es) * | 2002-12-10 | 2005-08-19 | Wyeth Corp | Derivados del acido 3-carbonil-1h-indol-1-ilacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1). |
| US7265148B2 (en) * | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
| US7446201B2 (en) * | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
| US7420083B2 (en) * | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
| US7141592B2 (en) * | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
| US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| US20050215626A1 (en) * | 2003-09-25 | 2005-09-29 | Wyeth | Substituted benzofuran oximes |
| US7342039B2 (en) * | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
| US7411083B2 (en) * | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
| US7351726B2 (en) * | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
| US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
| US7442805B2 (en) * | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| US7332521B2 (en) * | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
| US7534894B2 (en) * | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
| US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
| BRPI0514549A (pt) * | 2004-08-23 | 2008-06-17 | Wyeth Corp | ácidos de pirrol-naftila como inibidores de pai-1 |
| JP2008510815A (ja) * | 2004-08-23 | 2008-04-10 | ワイス | 血栓症および心臓血管疾患の治療にて有用な調節剤であるプラスミノゲン活性化因子阻害剤１型（ｐａｉ−１）としてのオキサゾロ−ナフチル酸 |
| WO2006023866A2 (en) * | 2004-08-23 | 2006-03-02 | Wyeth | Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1 |
| CN101263115A (zh) * | 2005-08-17 | 2008-09-10 | 惠氏公司 | 经取代吲哚和其用途 |
-
2007
- 2007-02-26 CA CA002643731A patent/CA2643731A1/en not_active Abandoned
- 2007-02-26 PE PE2007000203A patent/PE20071017A1/es not_active Application Discontinuation
- 2007-02-26 AU AU2007217363A patent/AU2007217363A1/en not_active Abandoned
- 2007-02-26 KR KR1020087018533A patent/KR20080108407A/ko not_active Withdrawn
- 2007-02-26 AR ARP070100784A patent/AR059629A1/es unknown
- 2007-02-26 US US11/679,031 patent/US20070203220A1/en not_active Abandoned
- 2007-02-26 WO PCT/US2007/005069 patent/WO2007098278A2/en not_active Ceased
- 2007-02-26 RU RU2008128475/15A patent/RU2008128475A/ru not_active Application Discontinuation
- 2007-02-26 TW TW096106440A patent/TW200744585A/zh unknown
- 2007-02-26 CN CNA2007800059111A patent/CN101384256A/zh active Pending
- 2007-02-26 EP EP07751803A patent/EP2010171A2/en not_active Withdrawn
- 2007-02-26 JP JP2008556476A patent/JP2009528290A/ja not_active Withdrawn
- 2007-02-26 MX MX2008011015A patent/MX2008011015A/es unknown
- 2007-02-26 BR BRPI0710964-4A patent/BRPI0710964A2/pt not_active IP Right Cessation
-
2008
- 2008-07-22 IL IL192975A patent/IL192975A0/en unknown
- 2008-08-05 NO NO20083438A patent/NO20083438L/no unknown
- 2008-08-25 GT GT200800167A patent/GT200800167A/es unknown
- 2008-08-26 ZA ZA200807357A patent/ZA200807357B/xx unknown
- 2008-08-26 EC EC2008008699A patent/ECSP088699A/es unknown
- 2008-08-27 CR CR10253A patent/CR10253A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200744585A (en) | 2007-12-16 |
| EP2010171A2 (en) | 2009-01-07 |
| KR20080108407A (ko) | 2008-12-15 |
| NO20083438L (no) | 2008-10-31 |
| IL192975A0 (en) | 2009-08-03 |
| WO2007098278A3 (en) | 2008-03-20 |
| US20070203220A1 (en) | 2007-08-30 |
| ECSP088699A (es) | 2008-09-29 |
| GT200800167A (es) | 2009-01-15 |
| AU2007217363A1 (en) | 2007-08-30 |
| CA2643731A1 (en) | 2007-08-30 |
| CR10253A (es) | 2008-11-18 |
| JP2009528290A (ja) | 2009-08-06 |
| WO2007098278A2 (en) | 2007-08-30 |
| CN101384256A (zh) | 2009-03-11 |
| PE20071017A1 (es) | 2007-11-12 |
| BRPI0710964A2 (pt) | 2012-02-28 |
| RU2008128475A (ru) | 2010-04-10 |
| MX2008011015A (es) | 2008-11-14 |
| ZA200807357B (en) | 2009-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059629A1 (es) | Inhibidores del inhibidor del activador de plasminogeno (pai- 1) para el tratamiento de trastornos musculares | |
| ECSP077980A (es) | Inhibidores de la actividad akt | |
| EA200900213A1 (ru) | Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич | |
| AR058901A1 (es) | Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende | |
| EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| ECSP099376A (es) | Inhibidores de la actividad de la akt | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| EA200971115A1 (ru) | Новые ингибиторы обратной транскриптазы вич | |
| MX2009003405A (es) | Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa. | |
| EA201001455A1 (ru) | Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3) | |
| EA201100030A1 (ru) | Пиразольные соединения 436 | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| CL2008003096A1 (es) | Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras. | |
| CR10288A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
| CY1113386T1 (el) | Αναστολεις πρωτεασωματος | |
| AR049956A1 (es) | DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS. | |
| AR085607A1 (es) | Inhibidores de la mst1 quinasa y metodos para su utilizacion | |
| AR069802A1 (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| CL2009000429A1 (es) | Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer. | |
| AR038202A1 (es) | Compuestos de indazol utiles como inhibidores de la proteina quinasa | |
| AR084433A1 (es) | Inhibidores de la faah y composiciones farmaceuticas que los contienen | |
| HN2011000874A (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
| CU20140068A7 (es) | Triazolopiridinas sustituidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |